Related Experiment Video

Updated: Dec 7, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.7K

Necessity of Antiaggregation and Anticoagulation and Its Prognostic Impact: A Cardiologist's View

Ulrich Hink1, Thomas Voigtländer2

  • 1Klinik für Innere Medizin 3 - Kardiologie, Angiologie und Internistische Intensivmedizin, Klinikum Frankfurt Höchst, Frankfurt, Germany.

Visceral Medicine
|October 2, 2020
PubMed

Insights

Anticoagulation and antiplatelet therapies improve outcomes in cardiovascular diseases but increase bleeding risk. Newer strategies, like direct oral anticoagulants, show promise in managing this risk, especially in atrial fibrillation patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis Research

Background:

  • Anticoagulation and antiplatelet therapies are fundamental in modern cardiovascular disease management.
  • A significant challenge in these treatments is the elevated risk of bleeding.

Purpose of the Study:

  • To review the prognostic relevance of anticoagulation and antiaggregation in cardiovascular diseases.
  • To discuss the balance between therapeutic benefits and bleeding risks associated with antithrombotic agents.

Main Methods:

  • Review of existing studies on antithrombotic treatment in various cardiovascular conditions.
  • Analysis of recent data comparing different anticoagulation and antiplatelet strategies.
  • Evaluation of bleeding risks in specific patient populations, including those with atrial fibrillation and after percutaneous coronary intervention.

Main Results:

  • Antithrombotic treatment positively impacts cardiovascular death across major cardiovascular diseases.
  • Reducing dual antiplatelet therapy (DAPT) duration is safe in high-bleeding-risk patients post-percutaneous coronary intervention.
  • Direct oral anticoagulants (DOACs) with P2Y12 inhibitors show safety compared to vitamin K antagonist (VKA) and DAPT, reducing bleeding risk in nonvalvular atrial fibrillation.
  • Antithrombotic therapy is beneficial in heart failure and after valve interventions.

Conclusions:

  • Anticoagulation and antiaggregation are crucial for prognosis in cardiovascular diseases.
  • Careful consideration of the inherent bleeding risk is essential when implementing these therapies.
Abstract

Keywords:
AntiaggregationAnticoagulationAntiplatelet therapyBleedingCardiologyCardiovascular disease

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.6K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
170
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
910
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
176
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.3K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.7K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
231